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Abstracts / Biol Blood Marrow Transplant 19 (2013) S167eS177 S175irradiation (TBI) conditioning prior to AHSCT. The impact of
palifermin on the incidence of mucositis in children
following AHSCT has never been studied. In this retrospec-
tive study, we compared the incidence of mucositis and
supportive care required in childrenwho received palifermin
vs. controls (no palifermin) during non-TBI AHSCT. Mucositis
was graded as per WHO criteria. The continuous variables
were summarized by the mean and standard deviation; the
categorical variables were summarized by percentage. The
palifermin vs. control group were compared by two-sided t-
test for continuous measurements and by Chi-square test for
categorical measurements. From 2005-2011, 58 patients
received myeloablative AHSCT, of which n¼25 were in the
palifermin group and n¼33 were in the control group.
Demographic characteristics are presented in Table.
Comparing palifermin vs. the control group: the average time
for neutrophil engraftment was 12.163.21 days vs. 11.5
1.68 (P¼.127), the incidence of grade I and III-IVmucositis
was 80% vs. 90.9%, and 20% (P¼ .02) vs. 42.4% (P¼.07), the
number of days with fever were 4.923.49 vs. 7.094.86
(P¼.063), the number of days patients received PCA were
8.808.39 vs. 8.308.54 (P¼.826), and the number of days
patients were on TPN were 13.5211.32 vs. 11.559.63
(P¼.484), respectively. The incidence of blood stream and
Clostridium difﬁcile infection was 36% vs. 27.3% (P¼.4) and
24% vs. 18.2% (P¼.5), respectively. The average length of
hospital stay 31.447.42 vs. 28.6110.38 (P¼.252) was not
statistically different between the palifermin and control
groups. In summary, we were unable to demonstrate that
there was a statistical difference with incidence of mucositis
and other supportive care needs or a decrease in hospital
stay in the palifermin group. In children receiving AHSCT,
palifermin should only be used in the setting of a large






Age 6.85 (5.49) 7.96 (6.19) .473
Gender:
Male 20 (60.6%) 14 (56%) .724
Female 13 (39.4%) 11 (44%)
Weight 30.62 (27.08) 35.02 (25.95) .535
BSA 0.98 (0.55) 1.05 (0.51) .580
Brain Tumor 15 (45.5%) 3 (12%) .024
Solid Tumor 11 (33.3%) 14 (56%)
Lymphoma 7 (21.2%) 8 (32%)
Disease Status .671
CR/PR 29 (87.9%) 21 (84.0%)
SD/PD 4 (16%) 4 (12.1%)
Prior Radiation: .120
Yes 3 (9.1%) 6 (24%)
No 30 (90.9%) 19 (76%)
HSV serostatus: .330
Positive 25 (75.8%) 16 (64%)
Negative 8 (24.2%) 9 (36%)
Creatinine clearance 118.1 (42.55) 134.8 (49.31) .176TRANSPLANT PHARMACY ORAL
121
Effectiveness of an Algorithm-Based Approach to
Filgrastim-Based Mobilization Using Predetermined
Decision Points for the Inclusion of Plerixafor
Andrea E. Faison 1, Eric Chow2, Tippu Khan 3,
Deborah Covington 4, Thomas C. Shea 5, Kamakshi V. Rao 6.
1 University of North Carolina Hospitals, NC; 2 Pharmacy,University of North Carolina Hospitals, Chapel Hill, NC;
3 Pharmacy, University of North Carolina, Chapel Hill, NC;
4UNC Hospitals, Chapel Hill, NC; 5 Department of Medicine,
UNC Lineberger Comprehensive Cancer Center, University of
North Carolina at Chapel Hill, Chapel Hill, NC; 6 Pharmacy,
University of North Carolina Hospitals and Clinics, Chapel Hill,
NC
Background: The use of ﬁlgrastimwith or without plerixafor
has been shown to be an effective modality for the mobili-
zation of peripheral blood stem cells. However, questions
remain as to the CD34+ count that would best predict for
efﬁcient collection. We developed a ﬁlgrastim-based mobi-
lization algorithm with a predetermined decision point for
the inclusion of plerixafor and a CD34+ count of 20 cells/uL as
the trigger for collection. The purpose of our evaluation was
to determine the efﬁcacy of this algorithm, as well as the
impact on plerixafor use, in patients undergoing mobiliza-
tion with ﬁlgrastim prior to autologous hematopoietic stem
cell transplant (HSCT).
Methods: Patients received ﬁlgrastim 10 mcg/kg SC once
daily for 4 days. If the day 5 CD34+ count was > 20/ul,
apheresis was started and ﬁlgrastim was continued until the
collection goal was met. If the day 5 CD34+ count was <10,
plerixafor was started, and if the day 5 CD34+ count was 10-
20, ﬁlgrastim was continued for 1 day with plerixafor added
if the day 6 CD34+ count remained <20/uL. Mobilization
efforts were stopped if the blood CD34+ count remained <
10. The CD34+ cell collection goal was 4 x 106 cells/kg, with
a minimum requirement of 2 x 106 to proceed to HSCT.
Results: To date, 21 patients (18 multiple myeloma and 3
other) have been treated. Fifteen of 18 myeloma patients
received prior lenalidomide therapy. Eleven of the 21
patients were successfully mobilized using ﬁlgrastim alone.
Nine patients who had inadequate CD34+ mobilization with
ﬁlgrastim alone responded to the addition of plerixafor.
Patients requiring plerixafor received an average of 1.56
doses. One patient with non-Hodgkin's lymphoma had no
response to ﬁlgrastim and therefore mobilization attempts
were halted. Seventeen of the 21 patients have successfully
proceeded to transplant, with 3 of the remaining 4 expected
to be admitted for HSCT within the next month. Patients
collected in an average of 1.7 apheresis sessions and collected
an average of 5.15 x 106 CD34+ cells/kg.
Conclusion: We demonstrate here a successful and cost-
effective algorithm-based approach to mobilization,
including a predetermined strategy to include plerixafor for
poormobilizers. By using a decision point for the inclusion or
exclusion of plerixafor, we avoided use of the agent in
patients unlikely to need it for successful collection.122
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Background: Chemotherapy plus GCSF has been an effective
modality for the mobilization of peripheral blood stem cells.
However, the optimal drug, dose, and schedule have not
